New RNA therapy aims to tame Out-of-Control immune system

NCT ID NCT07322718

Recruiting now Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new treatment called RXIM002 for people with severe autoimmune diseases that haven't responded to standard therapies. The treatment uses a special RNA molecule to create immune cells that target and destroy faulty B cells, which are causing the disease. The main goals are to check if the treatment is safe and to see how long the modified cells stay in the body. About 27 adults aged 18 to 65 with conditions like lupus are being enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease autoimmune hemolytic anemia idiopathic inflammatory myopathy lupus nephritis membranous glomerulonephritis Recurrence systemic lupus erythematosus systemic sclerosis thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY B CELL-MEDIATED AUTOIMMUNE DISEASES

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ruijin Hospital
RECRUITING

Shanghai, Huangpu District, No. 197, Ruijin 2nd Road, China

Contact Phone: •••-•••-•••• Email: •••••@•••••